Evogene director buys 460,000 company shares

Evogene Ltd. director Leon Recanati reported purchasing 460,000 Ordinary Shares on August 11, 2026 at $0.635 per share in an open-market or private transaction.

Rhea-AI Filing Summary

Evogene Ltd. director Leon Recanati reported purchasing 460,000 Ordinary Shares on August 11, 2026 at $0.635 per share in an open-market or private transaction. Following this trade, he directly holds 1,343,886 Ordinary Shares. The filing also lists several existing stock option awards over Ordinary Shares at exercise prices ranging from $1.29 to $54.32 with expirations between 2027 and 2035; per the footnotes, these option rows reflect holdings only and no new transactions.

Insider Trade Summary

Net Buyer: 460,000 shares

Net Buy 11 txns

Insider RECANATI LEON

Role Director

Bought 460,000 shs ($292K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	460,000	$0.635	$292K
holding	Stock Option (right to buy) F1	--	--	--
holding	Stock Option (right to buy) F1	--	--	--
holding	Stock Option (right to buy) F1	--	--	--
holding	Stock Option (right to buy) F1	--	--	--
holding	Stock Option (right to buy) F1	--	--	--
holding	Stock Option (right to buy) F1	--	--	--
holding	Stock Option (right to buy) F1	--	--	--
holding	Stock Option (right to buy) F1	--	--	--
holding	Stock Option (right to buy) F1	--	--	--
holding	Stock Option (right to buy) F1, F2	--	--	--

Holdings After Transaction: Ordinary Shares — 1,343,886 shares (Direct); Stock Option (right to buy) — 10,950 contracts (Direct)

Footnotes (2)

1. F1. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
2. F2. The options reported in this row vest equally on a quarterly basis (25% per quarter) such that they will be fully vested by the one-year anniversary of the August 18, 2025 grant date.

Key Figures

Shares purchased: 460,000 Ordinary Shares Purchase price: $0.635 per share Shares owned after transaction: 1,343,886 Ordinary Shares +4 more

7 metrics

Shares purchased 460,000 Ordinary Shares Non-derivative purchase on August 11, 2026

Purchase price $0.635 per share Price for 460,000 Ordinary Shares purchased

Shares owned after transaction 1,343,886 Ordinary Shares Direct ownership following the reported purchase

Highest option exercise price $54.3200 Stock option over 250 Ordinary Shares expiring May 16, 2027

Lowest option exercise price $1.2900 Stock option over 2,500 Ordinary Shares expiring August 18, 2035

Representative option tranche size 1,800 underlying Ordinary Shares Several option grants with 1,800 underlying shares each

Latest option grant vesting rate 25% per quarter Options granted August 18, 2025 vest equally each quarter over one year

Key Terms

Ordinary Shares, Stock Option (right to buy), exercise price, expiration date, +1 more

5 terms

Ordinary Shares financial

"460,000 Ordinary Shares purchased at $0.635 per share"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Stock Option (right to buy) financial

"Stock Option (right to buy) over Evogene Ordinary Shares"

exercise price financial

"stock options with exercise prices from $1.29 to $54.32"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"option expirations between 2027 and 2035"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest equally on a quarterly basis financial

"options vest equally on a quarterly basis (25% per quarter)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Evogene (EVGN) director Leon Recanati report in this Form 4?

Leon Recanati reported a purchase of 460,000 Evogene Ordinary Shares at $0.635 per share. After this transaction, he directly holds 1,343,886 Ordinary Shares, according to the Form 4 filing.

How many Evogene (EVGN) shares does Leon Recanati own after the reported trade?

After the reported transaction, Leon Recanati directly owns 1,343,886 Ordinary Shares of Evogene. This figure includes his existing holdings plus the 460,000 shares purchased on August 11, 2026.

At what price were the Evogene (EVGN) shares purchased in the Form 4?

The reported purchase was made at a price of $0.635 per Ordinary Share. The transaction involved 460,000 shares, described as a purchase in an open-market or private transaction on August 11, 2026.

Does the Evogene (EVGN) Form 4 show any insider share sales?

No insider share sales are reported. The Form 4 shows a net buy position, with 460,000 shares purchased and no sales, gifts, or option exercises disclosed for the period covered.

What stock options for Evogene (EVGN) does Leon Recanati hold according to this filing?

The filing lists multiple stock options (rights to buy) over Evogene Ordinary Shares, with exercise prices from $1.29 to $54.32 and expirations between 2027 and 2035. Footnotes state these rows reflect existing holdings only, not new transactions.

How many Evogene (EVGN) shares are underlying Leon Recanati’s reported stock options?

The derivative holdings table shows several option grants over Ordinary Shares, including tranches of 250, 1,800, and 2,500 underlying shares each. These options have various exercise prices and expirations and are reported as existing positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 07:00 AM Accepted by SEC EDGAR 08/13/2026 - 07:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RECANATI LEON

(Last) (First) (Middle)

27 YOAV ST.

(Street)

TEL AVIV 6908165

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evogene Ltd. [ EVGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol
[EVGN]

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/11/2026		P		460,000	A	$0.635	1,343,886	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$54.32							06/11/2021	05/16/2027	Ordinary Shares	250		250	D
Stock Option (right to buy)(1)	$32.05							06/11/2022	06/25/2028	Ordinary Shares	250		250	D
Stock Option (right to buy)(1)	$17.68							06/11/2023	07/30/2029	Ordinary Shares	250		250	D
Stock Option (right to buy)(1)	$12.03							06/11/2024	11/17/2030	Ordinary Shares	250		250	D
Stock Option (right to buy)(1)	$39.32							06/11/2025	06/11/2031	Ordinary Shares	250		250	D
Stock Option (right to buy)(1)	$28.62							08/10/2022	09/01/2031	Ordinary Shares	1,800		1,800	D
Stock Option (right to buy)(1)	$10.5							09/15/2023	09/15/2032	Ordinary Shares	1,800		1,800	D
Stock Option (right to buy)(1)	$6.03							05/11/2024	05/11/2033	Ordinary Shares	1,800		1,800	D
Stock Option (right to buy)(1)	$7.16							06/13/2025	06/13/2034	Ordinary Shares	1,800		1,800	D
Stock Option (right to buy)(1)	$1.29							(2)	08/18/2035	Ordinary Shares	2,500		2,500	D

Explanation of Responses:

1. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

2. The options reported in this row vest equally on a quarterly basis (25% per quarter) such that they will be fully vested by the one-year anniversary of the August 18, 2025 grant date.

Remarks:

Exhibit 24.1 - Power of Attorney.

	/s/ Nitsan Deutsch, Attorney-in-fact	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)